Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer

Clinical Genitourinary Cancer

Volumn 5, Issue 2, 2006, Pages 150-154

  Jin, James O ^a   Lehmann, Jan ^b   Taxy, Jerome ^c   Huo, Dezheng ^c   Stöckle, Michael ^b   Vogelzang, Nicholas J ^a   Steinberg, Gary ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c Department of Pathology ^*

Author keywords

Adjuvant chemotherapy; P16; P53; Prb

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PILOT STUDY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 34547732470     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.032     Document Type: Article

References (21)

1. Davis NB, Stadler WM. Genitourinary malignancies: bladder/penis/urethral cancers. In: Vokes EE, Golomb HM, eds. Oncologic Therapies. Berlin, Heidelberg: Springer-Verlag; 2003:521-530.
2. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533-540.
3. Grossman HB, Natale RB, Tange CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866.
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361:1927-1934.
5. Pectasides D., Pectasides M., Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 2005; 48:60-67.
6. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066-1073.
7. Logothetis CJ, Dexeus FH, Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050-1055.
8. Bamias A., Aravantinos G., Bafaloukos D., et al. Docetaxel plus cisplatin versus MVAC in advanced urothelial carcinoma: a multicenter, randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Proc Am Soc Clin Oncol 2003; 22:384 (Abstract #1541).
9. von der MH, Hansen SW, Roberts J. T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
10. von der MH, Sengelov L., Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608.
11. Droz J. P., Fizazi K., Beuzeboc P., et al. Gemcitabine and cisplatin (GC) as adjuvant chemotherapy for locally advanced bladder cancer (LABC) after cystectomy: preliminary results of a feasibility study. Proc Am Soc Clin Oncol 2002; 21:153b (Abstract #2425).
12. El-Khoueiry AB, Tagawa ST, Quinn DI, et al. Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: a USC experience with molecular correlates. J Clin Oncol 2004; 23:415 (Abstract #4639).
13. Meliani E., Lapini A., Serni S., et al. Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Urol Int 2003; 71:37-40.
14. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induce and cisplatin-induced toxicities: result of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101-2112.
15. Chatterjee SJ, Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22:1007-1013.
16. Shariat S. F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22:1014-1024.
17. Moore MJ, Winquist EW, Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17:2876-2881.
18. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18:1921-1927.
19. Cote R., Esrig D., Groshen S., et al. p53 and the treatment of bladder cancer. Nature 1997; 385:123-125.
20. Korkolopoulou P., Christodoulou P., Lazaris A., et al. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multi-variate analysis including p53 expression and proliferation markers. Eur Urol 2001; 39:167-177.
21. Benedict W. F., Lerner SP, Zhou J., et al. Levels of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18:1197-1203.